Clinical Trials Browser

Breast Neoplasms

Carcinoma, Intraductal, Noninfiltrating

Breast Neoplasms

Advanced Breast Carcinoma

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Anatomic Stage III Breast Cancer AJCC v8

Locoregional Recurrence

Breast Neoplasms

Breast Neoplasms, Carcinoma, Ductal

Endometrial Stromal Tumors

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

ER+ Breast Cancer

Breast Neoplasms, Neoplasm Metastasis

Primary Breast Cancer ER+ve

Estrogen-receptor Positive Invasive Metastatic Breast Cancer

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Cancer Metastatic

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Metastatic Beast Cancer

Breast Neoplasms

Breast Neoplasms

Clinical Trials

CAMERAN

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

COMBINE-01

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

RaPhLRR

ADEPT

BabyTEARS

BFR-ESS

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

BabyTears

POWER

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

METALLICA

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

ASPIRE

TRAK-ER

POLLY

ARB

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

NeoTEE

PEARL

AMICA

Exemestane in Post-Menopausal Women With NSCLC

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

SEAT

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

BOOSTER

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors

PREDIX LumB

FATIMA

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

GIADA

Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer

PREDIX LumA

Exemestane-RAD001-Metformin

Exemestane and Cyclophosphamide for Metastatic Breast Cancer

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.